Abstract
Hypertension affects 30–40% of the adult population in the developed world and is a major risk factor for stroke, myocardial infarction, heart failure, and kidney failure. Though the importance of controlling hypertension is well recognized, only about 50% of patients in the United States actually attain guideline recommended blood pressure goals. Limiting factors include patient noncompliance, suboptimal application of effective medication, and true medication resistance. Renal sympathetic denervation has been used to treat resistant hypertension and appears to be safe and effective and to produce durable results. We hypothesize that renal sympathetic denervation will produce similar results across the spectrum of hypertension severity for which pharmacologic therapy is currently indicated and propose that this is an important hypothesis to be tested in suitably powered randomized trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
